financetom
Business
financetom
/
Business
/
Barclays Kept Cap on Bankers' Bonuses in 2023, Chair Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Barclays Kept Cap on Bankers' Bonuses in 2023, Chair Says
Apr 3, 2024 7:49 AM

10:25 AM EDT, 04/03/2024 (MT Newswires) -- Barclays ( JJCTF ) kept a cap on the bonuses paid to bankers in 2023 even after UK regulators lifted a requirement for the country's banks to apply a maximum ratio of variable to fixed remuneration at no more than 2-to-1, the bank's Chairman Nigel Higgins said in a letter to shareholders before the company's May 9 annual meeting.

The UK regulatory requirement, which was lifted in October 2023, applied to bankers whose activities may have a material impact on the bank's risk profile, known as material risk takers.

The bank's board remuneration committee decided the 2-1 cap" would continue to apply in Barclays ( JJCTF ) for the 2023 performance year and that it would consider this further in respect of 2024 and future years," Higgins said in the letter.

The policy may be changed in the future, Higgins said.

"Whether or not the company changes the cap in the future, pay across the group will continue to be managed in line with

Barclays' ( JJCTF ) remuneration philosophy, which includes a focus on rewarding sustainable performance," he said.

Price: 9.64, Change: +0.22, Percent Change: +2.34

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ECARX's Antora 1000 Pro Receives ASPICE v4.0 CL3 Certification
ECARX's Antora 1000 Pro Receives ASPICE v4.0 CL3 Certification
Aug 27, 2025
07:29 AM EDT, 08/27/2025 (MT Newswires) -- ECARX ( ECX ) said Wednesday its Antora 1000 Pro computing platform has received Automotive SPICE v4.0 Capability Level 3 (CL3) certification. The platform previously obtained the ASPICE v3.1 CL2 certification in September 2020, CMMI CL3 accreditation in May 2022, and ASPICE v3.1 CL3 certification in August 2022. ...
J.M. Smucker Fiscal Q1 Adjusted Earnings, Sales Fall; Full-Year Revenue Outlook Updated
J.M. Smucker Fiscal Q1 Adjusted Earnings, Sales Fall; Full-Year Revenue Outlook Updated
Aug 27, 2025
07:29 AM EDT, 08/27/2025 (MT Newswires) -- J.M. Smucker (SJM) reported fiscal Q1 adjusted earnings Wednesday of $1.90 per diluted share, down from $2.44 a year earlier. Analysts polled by FactSet expected $1.93. Net sales for the quarter ended July 31 were $2.11 billion, compared with $2.13 billion a year earlier. Analysts surveyed by FactSet expected $2.12 billion. For fiscal...
Kohl's Fiscal Q2 Adjusted Earnings, Net Sales Fall; 2025 Outlook Revised
Kohl's Fiscal Q2 Adjusted Earnings, Net Sales Fall; 2025 Outlook Revised
Aug 27, 2025
07:29 AM EDT, 08/27/2025 (MT Newswires) -- Kohl's (KSS) reported fiscal Q2 adjusted earnings Wednesday of $0.56 per diluted share, down from $0.59 a year earlier. Analysts polled by FactSet expected $0.30. Net sales for the quarter ended Aug. 2 were $3.35 billion, compared with $3.53 billion a year earlier. Analysts surveyed by FactSet expected $3.32 billion. For fiscal 2025,...
Merck's Phase 3 Trial for Metastatic Breast Cancer Treatment Doses First Patient
Merck's Phase 3 Trial for Metastatic Breast Cancer Treatment Doses First Patient
Aug 27, 2025
07:28 AM EDT, 08/27/2025 (MT Newswires) -- Merck ( MRK ) said Wednesday its phase 3 trial for investigational patritumab deruxtecan targeting metastatic breast cancer has dosed its first patient. The trial evaluates the efficacy and safety of investigational patritumab deruxtecan versus investigator's choice of treatment in patients with unresectable locally advanced or metastatic hormone receptor positive, HER2 negative breast...
Copyright 2023-2026 - www.financetom.com All Rights Reserved